

Supplemental Table B: Mean Changes During Double-Blind Period in Safety Parameters (Safety Population)

Parameter	Placebo n=147		Cariprazine 3-6 mg/d n=151		Cariprazine 6-9 mg/d n=148	
	n	Mean (SD) ^a	n	Mean (SD) ^a	n	Mean (SD) ^a
Vital Signs						
Systolic blood pressure, mmHg	145	-0.2 (10.0)	148	1.9 (9.8)	147	1.7 (9.9)
Diastolic blood pressure, mmHg	145	-0.5 (8.2)	148	1.7 (8.3)	147	2.8 (7.8)
Pulse, bpm	145	-0.4 (10.8)	148	1.1 (10.5)	147	0.8 (10.4)
Body weight, kg	145	0.7 (2.6)	148	0.9 (2.7)	147	1.2 (2.7)
BMI, kg/m²	145	0.2 (0.9)	148	0.3 (0.9)	147	0.4 (0.9)
Waist circumference, cm	133	1.4 (9.9)	128	0.3 (4.2)	128	1.1 (4.9)
Liver Enzymes						
Alanine aminotransferase, U/L	143	1.3 (13.9)	142	5.0 (26.0)	139	13.5 (42.7)
Aspartate aminotransferase, U/L	143	0.7 (9.4)	142	2.8 (12.3)	138	4.6 (19.8)
Alkaline phosphatase, U/L	143	-0.9 (14.2)	142	0.3 (13.2)	139	-0.7 (15.0)
Total bilirubin, mg/dL	143	0.0 (0.2)	142	0.1 (0.2)	140	0.0 (0.3)
Metabolic Parameters						
Total cholesterol, mg/dL	143	0.6 (35.4)	142	-7.4 (31.9)	139	3.0 (33.0)
LDL cholesterol, mg/dL	143	0.3 (30.4)	142	-3.5 (26.6)	139	0.5 (29.2)
HDL cholesterol, mg/dL	143	-1.1 (9.4)	142	-0.9 (10.8)	139	-0.1 (11.2)
Triglycerides, mg/dL	143	7.5 (71.6)	142	-15.7 (83.1)	139	12.8 (75.2)
Fasting glucose, mg/dL	134	2.5 (17.6)	135	7.1 (17.8)	125	3.2 (14.9)
Prolactin						
Prolactin, ng/mL	136	-5.6 (23.1)	129	-7.3 (19.9)	124	-14.8 (33.1)
Extrapyramidal Symptoms						
AIMS total score	145	-0.1 (0.7)	147	0.1 (0.6)	147	0.0 (0.6)
BARS total score	145	0.0 (0.9)	147	0.2 (1.1)	147	0.1 (1.2)
SAS total score	145	0.0 (1.5)	147	0.1 (1.4)	147	0.6 (2.0)

*Patients with baseline value and ≥ 1 postbaseline assessment; analyses based on changes from baseline to last available postbaseline assessment in the double-blind period. Abbreviations: AIMS, Abnormal Involuntary Movement Scale; BARS, Barnes Akathisia Rating Scale; BMI, body mass index; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SAS, Simpson-Angus Scale.